Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.62 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.62 |
| ▸ | GAA | P10253 | 2/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.56 |
| ▸ | PHGDH | O43175 | 4/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | CCR6 | P51684 | 2/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.46 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5597876 | 0.80 | MAPT (0.60) | MAPTNPSR1GAAL3MBTL1MAPK1 | |
| SCHEMBL5597895 | 0.77 | MAPT (0.52) | MAPTGAAMAPK1MEN1KMT2A | |
| SCHEMBL5597478 | 0.75 | FAAH (0.61) | MAPTNPSR1MAPK1LMNAALDH1A1 | |
| SCHEMBL5597630 | 0.75 | NPSR1 (0.47) | MAPTNPSR1GAAMAPK1MEN1 | |
| SCHEMBL5597639 | 0.74 | FAAH (0.49) | MAPTNPSR1MAPK1TDP1ALDH1A1 | |
| SCHEMBL5597558 | 0.74 | PKM (0.46) | MAPTNPSR1GAAMAPK1MEN1 | |
| SCHEMBL15911569 | 0.74 | MAPT (0.67) | MAPTNPSR1GAAL3MBTL1MAPK1 | |
| SCHEMBL5597622 | 0.73 | POLB (0.51) | MAPTNPSR1MAPK1LMNACYP2D6 | |
| SCHEMBL7113264 | 0.73 | MAPT (0.53) | MAPTNPSR1GAAL3MBTL1MAPK1 | |
| SCHEMBL28322333 | 0.73 | MAPT (0.69) | MAPTNPSR1GAAL3MBTL1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1202734-B1 | 3(5)-UREIDO-PYRAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ANTITUMOR AGENTS | PFIZER ITALIA SRL (IT) | 2007-05-02 | — | — | EP | claimed |
| EP-1202734-A4 | 3(5)-UREIDO-PYRAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ANTITUMOR AGENTS | PHARMACIA ITALIA SPA (IT) | 2004-09-01 | — | — | EP | claimed |
| JP-2003507328-A | — | — | 2003-02-25 | — | — | JP | claimed |
| US-6387900-B1 | ANTICANCER AGENTS | PHARMACIA & UPJOHN S.P.A. (IT) | 2002-05-14 | — | — | US | claimed |
| EP-1202734-A1 | 3(5)-UREIDO-PYRAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ANTITUMOR AGENTS | Pharmacia Italia S.p.A. (IT) | 2002-05-08 | — | — | EP | claimed |
| WO-2001012188-A1 | 3(5)-UREIDO-PYRAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ANTITUMOR AGENTS | PHARMACIA & UPJOHN S.P.A. (IT) | 2001-02-22 | — | — | WO | claimed |
| EP-1202734-B1 | 3(5)-UREIDO-PYRAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ANTITUMOR AGENTS | PFIZER ITALIA SRL (IT) | 2007-05-02 | — | — | EP | disclosed |
| EP-1202734-A4 | 3(5)-UREIDO-PYRAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ANTITUMOR AGENTS | PHARMACIA ITALIA SPA (IT) | 2004-09-01 | — | — | EP | disclosed |
| US-6387900-B1 | ANTICANCER AGENTS | PHARMACIA & UPJOHN S.P.A. (IT) | 2002-05-14 | — | — | US | disclosed |
| EP-1202734-A1 | 3(5)-UREIDO-PYRAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ANTITUMOR AGENTS | Pharmacia Italia S.p.A. (IT) | 2002-05-08 | — | — | EP | disclosed |
| WO-2001012188-A1 | 3(5)-UREIDO-PYRAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ANTITUMOR AGENTS | PHARMACIA & UPJOHN S.P.A. (IT) | 2001-02-22 | — | — | WO | disclosed |